More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $145.65 |
|
|||
| Open | $145.65 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $145.65 | ||||
| Day Low | $145.65 | ||||
| P/E | 80.47 | ||||
| EPS | $1.81 | ||||
| Volume | 266 | ||||
- Gilead Sciences (GILD) PT Raised to $175 at HSBC
- Assembly Bio exercises U.S. profit-share option with Gilead for herpes program
- Form 4 GILEAD SCIENCES, INC. For: Aug 26 Filed by: WELTERS ANTHONY
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
- U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
- Form 144 GILEAD SCIENCES, INC. Filed by: WELTERS ANTHONY
- Form N-PX GILEAD SCIENCES, INC. For: Jun 30
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
